Human Immunodeficiency Virus–Infected Persons with Mutations Conferring Resistance to Zidovudine Show Reduced Virologic Responses to Hydroxyurea and Stavudine‐Lamivudine

Open Access
Publisher Website
Google Scholar
Abstract
The baseline predictors of poor virologic response (P = .02) for use of lower dose hydroxyurea (500 mg/day) and 14.7 (95% CI, 1.1–200; P = .04) for the presence of a zidovudine-related mutation. For the stavudine-lamivudine study, the OR of failure to achieve a virologie response at 4 weeks in a multivariate logistic regression model was 23 (95% CI, 2.7–199; P = .004) for the presence of a mutation at codon 215.